Search
LABA/LAMA glucocorticoid combination (triple therapy)
Indications:
- maintenance treatment of moderate to severe COPD
- predominantly benefits patients with elevated blood eosinophil count (> 300 x 10E6/L) [1]
Laboratory:
- complete blood count
- eosinophil count: > 300 x 10E6/L
Specific
budesonide/formoterol/glycopyrrolate (Breztri Aerosphere)
fluticasone/umeclidinium/vilanterol (Trelegy Ellipta)
formoterol/fumarate/mometasone
General
pharmacologic combination
References
- Labaki WW, Rosenberg SR.
Chronic obstructive pulmonary disease.
Ann Intern Med 2020 Aug 4; 173:ITC17
PMID: 32745458
- Agusti A, Celli BR, Criner GJ et al.
Global Initiative for Chronic Obstructive Lung Disease 2023 Report:
GOLD executive summary.
Am J Respir Crit Care Med. 2023 Apr 1;207(7):819-837.
PMID: 36856433 PMCID: PMC10111975 Free PMC article
https://www.atsjournals.org/doi/10.1164/rccm.202301-0106PP
Components
inhaled glucocorticoid
long-acting beta adrenergic receptor agonist (LABA)
long-acting muscarinic receptor antagonist (LAMA)